Randomised, single-blind, single dose, crossover studies in 196 healthy volunteers showed that the pharmacokinetic profile of Biograstim was comparable to that of the reference product after subcutaneous and intravenous administration.
Randomiserede, enkeltblinde, crossover- forsøg med enkeltdosis, der omfattede 196 raske forsøgspersoner, viste, at Biograstims farmakokinetiske profil var sammenlignelig med profilen af referenceproduktet efter subkutan og intravenøs administration.